WALTHAM, Mass., Sept. 28, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR) (the "Company"), a global leader in rapid diagnostic
Alere issued the following statement:
We have cooperated with the SEC and we are pleased to fully resolve this matter.
Under the terms of the settlement, Alere agreed to pay approximately $13 million to the SEC and consented to the entry by the SEC of an administrative cease-and-desist order, issued today by the SEC, without admitting or denying the findings in the order.
About Alere Alere believes that when diagnosing and monitoring health conditions, Knowing now matters™. Alere delivers reliable and actionable information by providing rapid diagnostic tests, enhancing clinical and economic healthcare outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for cardiometabolic disease, infectious disease and toxicology. For more information on Alere, please visit www.alere.com.
View original content:http://www.prnewswire.com/news-releases/alere-announces-settlement-with-sec-300527648.html
SOURCE Alere Inc.
Subscribe to our Free Newsletters!
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...
Hashimoto's thyroiditis is an autoimmune disorder of the thyroid causing hypothyroidism. Synthetic ...
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...View All